secwatch.observer — SEC 8-K summary
======================================

Issuer:     Esperion Therapeutics, Inc. (ESPR)
CIK:        0001434868
Form:       8-K
Filed at:   2026-07-13T13:10:49+00:00
Accession:  0001104659-26-082926
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 1.01, 1.02, 2.01, 2.03, 3.01, 3.03, 5.01, 5.03, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Esperion acquired by Essence Parent for $3.16/share plus CVRs; merger closed July 13, 2026
--------------------------------------------------------------------------------

- Merger closed; shareholders received $3.16 per share cash plus one CVR per share.
- CVRs entitle holders to up to $100M aggregate milestone payments based on net sales of bempedoic acid products.
- Company delisted from Nasdaq; board replaced with Justin Bateman and Ankit Pareek.
- Prior credit agreement terminated; new loan agreement with BioPharma Credit entered.
- Convertible notes terms adjusted: each $1,000 principal convertible into $1,032.68 cash plus 326.7974 CVRs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434868/000110465926082926/0001104659-26-082926-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434868/000110465926082926/tm2620034d3_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-082926

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer